Literature DB >> 20972203

Clinical relevance of brain volume changes in patients with cerebrotendinous xanthomatosis.

S Guerrera1, M L Stromillo, A Mignarri, M Battaglini, S Marino, C Di Perri, A Federico, M T Dotti, N De Stefano.   

Abstract

OBJECTIVE: To quantify total and regional brain damage in subjects with cerebrotendinous xanthomatosis (CTX) using MR based quantitative measures.
BACKGROUND: CTX is a rare inherited disorder characterised by progressive neurological impairment. Appropriate therapy can slow disease progression. Measures of brain volume changes have been used in several neurological disorders due to their value in assessing disease outcome and monitoring patients' evolution.
METHODS: 24 CTX patients underwent conventional MRI to measure total and regional brain volumes. In five CTX patients who started therapy at baseline, clinical and MRI examinations were repeated after 2 years. Clinical disability, overall cognitive performance and cerebellar function were evaluated using the modified Rankin Scale (RS), Mini Mental Status Examination (MMSE) and cerebellar functional system score (CB-FSS).
RESULTS: Measures of normalised brain, cortical and cerebellar volumes were lower in CTX patients than in healthy controls (p<0.01). Instead, there were no differences in normalised white matter volumes between the two groups (p=0.1). At regional analysis, a significant volume decrease was found in each cortical region (p<0.01 for all regions). Normalised cortical volumes correlated closely with age (r=-0.9, p<0.0001), RS (r=-0.65, p<0.001) and MMSE (r=-0.60, p<0.01). Normalised cerebellar volumes correlated closely with CB-FSS scores (r=-0.58, p<0.01). In the five CTX patients followed over time, the annual brain volume decrease was -1.1 ± 0.2%.
CONCLUSIONS: Cortical volume, rather than white matter volume, is diffusely decreased in CTX patients and correlates closely with the patient's clinical status. These data provide evidence for the presence of clinically relevant neuronal-axonal damage in the brains of CTX patients.

Entities:  

Mesh:

Year:  2010        PMID: 20972203     DOI: 10.1136/jnnp.2009.203364

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  10 in total

1.  Polyneuropathy in cerebrotendinous xanthomatosis and response to treatment with chenodeoxycholic acid.

Authors:  F Ginanneschi; A Mignarri; M Mondelli; G N Gallus; M Del Puppo; S Giorgi; A Federico; A Rossi; M T Dotti
Journal:  J Neurol       Date:  2012-08-10       Impact factor: 4.849

2.  Structural and metabolic damage in brains of patients with SPG11-related spastic paraplegia as detected by quantitative MRI.

Authors:  Maria Laura Stromillo; Alessandro Malandrini; Maria Teresa Dotti; Marco Battaglini; Federico Borgogni; Alessandra Tessa; Eugenia Storti; Paola S Denora; Filippo Maria Santorelli; Carmen Gaudiano; Carla Battisti; Antonio Federico; Nicola De Stefano
Journal:  J Neurol       Date:  2011-05-29       Impact factor: 4.849

3.  The spectrum of magnetic resonance findings in cerebrotendinous xanthomatosis: redefinition and evidence of new markers of disease progression.

Authors:  Andrea Mignarri; Maria Teresa Dotti; Antonio Federico; Nicola De Stefano; Marco Battaglini; Irene Grazzini; Paolo Galluzzi; Lucia Monti
Journal:  J Neurol       Date:  2017-03-21       Impact factor: 4.849

4.  Treatment with chenodeoxycholic acid in cerebrotendinous xanthomatosis: clinical, neurophysiological, and quantitative brain structural outcomes.

Authors:  Maria Del Mar Amador; Marion Masingue; Rabab Debs; Foudil Lamari; Vincent Perlbarg; Emmanuel Roze; Bertrand Degos; Fanny Mochel
Journal:  J Inherit Metab Dis       Date:  2018-03-20       Impact factor: 4.982

5.  The role of dentate nuclei in human oculomotor control: insights from cerebrotendinous xanthomatosis.

Authors:  Francesca Rosini; Elena Pretegiani; Andrea Mignarri; Lance M Optican; Valeria Serchi; Nicola De Stefano; Marco Battaglini; Lucia Monti; Maria T Dotti; Antonio Federico; Alessandra Rufa
Journal:  J Physiol       Date:  2017-03-14       Impact factor: 5.182

6.  Clinical relevance and neurophysiological correlates of spasticity in cerebrotendinous xanthomatosis.

Authors:  A Mignarri; S Rossi; M Ballerini; G N Gallus; M Del Puppo; P Galluzzi; A Federico; M T Dotti
Journal:  J Neurol       Date:  2010-11-21       Impact factor: 4.849

Review 7.  The neuropsychiatry of inborn errors of metabolism.

Authors:  Mark Walterfang; Olivier Bonnot; Ramon Mocellin; Dennis Velakoulis
Journal:  J Inherit Metab Dis       Date:  2013-05-23       Impact factor: 4.982

Review 8.  Epidemiology, diagnosis, and treatment of cerebrotendinous xanthomatosis (CTX).

Authors:  Gerald Salen; Robert D Steiner
Journal:  J Inherit Metab Dis       Date:  2017-10-04       Impact factor: 4.982

Review 9.  Cerebrotendinous xanthomatosis: a comprehensive review of pathogenesis, clinical manifestations, diagnosis, and management.

Authors:  Shuke Nie; Guiqin Chen; Xuebing Cao; Yunjian Zhang
Journal:  Orphanet J Rare Dis       Date:  2014-11-26       Impact factor: 4.123

10.  Cerebrotendinous Xanthomatosis: Molecular Pathogenesis, Clinical Spectrum, Diagnosis, and Disease-Modifying Treatments.

Authors:  Shingo Koyama; Yoshiki Sekijima; Masatsune Ogura; Mika Hori; Kota Matsuki; Takashi Miida; Mariko Harada-Shiba
Journal:  J Atheroscler Thromb       Date:  2021-05-08       Impact factor: 4.928

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.